Assetmark Inc. Decreases Position in AbbVie Inc. $ABBV

Assetmark Inc. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 39.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,423 shares of the company’s stock after selling 66,549 shares during the quarter. Assetmark Inc.’s holdings in AbbVie were worth $18,640,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. HBK Sorce Advisory LLC raised its position in AbbVie by 2.3% in the 2nd quarter. HBK Sorce Advisory LLC now owns 20,995 shares of the company’s stock worth $3,897,000 after purchasing an additional 473 shares during the period. Buck Wealth Strategies LLC raised its position in AbbVie by 49.2% in the 2nd quarter. Buck Wealth Strategies LLC now owns 2,209 shares of the company’s stock worth $410,000 after purchasing an additional 728 shares during the period. Arkadios Wealth Advisors raised its position in AbbVie by 10.4% in the 2nd quarter. Arkadios Wealth Advisors now owns 42,008 shares of the company’s stock worth $7,798,000 after purchasing an additional 3,963 shares during the period. World Investment Advisors raised its position in AbbVie by 57.2% in the 2nd quarter. World Investment Advisors now owns 104,114 shares of the company’s stock worth $19,326,000 after purchasing an additional 37,866 shares during the period. Finally, Daymark Wealth Partners LLC raised its position in AbbVie by 2.9% in the 2nd quarter. Daymark Wealth Partners LLC now owns 81,814 shares of the company’s stock worth $15,186,000 after purchasing an additional 2,276 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Raymond James Financial restated an “outperform” rating and issued a $250.00 price objective (up previously from $236.00) on shares of AbbVie in a research report on Friday, October 17th. Daiwa Capital Markets upgraded shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective on the stock in a research report on Thursday, August 7th. Piper Sandler boosted their price objective on shares of AbbVie from $231.00 to $284.00 and gave the company an “overweight” rating in a research report on Friday, October 10th. UBS Group set a $251.00 price objective on shares of AbbVie in a research report on Friday, October 3rd. Finally, Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $234.80.

AbbVie Price Performance

Shares of NYSE ABBV opened at $218.14 on Friday. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61. The company’s 50-day moving average is $222.42 and its 200 day moving average is $200.77. The stock has a market capitalization of $385.35 billion, a P/E ratio of 103.87, a P/E/G ratio of 1.42 and a beta of 0.51.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s payout ratio is presently 312.38%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.